Accelerating the development of new treatment regimens for Tuberculosis
Worldwide, Tuberculosis (TB) is one of the top 10 causes of death and the leading cause from a single infectious agent. With 30 partners from 13 countries, UNITE4TB aims to set a new standard for anti-TB regimen development. It will upgrade current clinical trial methodology and enhance the efficiency with which new regimens are delivered.
UNITE4TB will follow an overarching racetrack concept to deliver an efficient, global clinical trials network equipped to implement phase 2 trials that conform to the highest regulatory standards